Study Links Psychedelics and Meditation to Distinct Brain Connectivity Changes

What happens inside a meditator's brain when you add an ayahuasca-inspired compound to a three-day silent retreat? A new randomized, double-blind, placebo-controlled pharmaco-fMRI study led by Klemens Egger and colleagues found a striking answer: meditation and psychedelics don't just produce different experiences, they pull functional connectivity in opposite directions.

The study, published in Imaging Neuroscience on September 29, 2025, enrolled 40 meditation practitioners in a three-day retreat setting and randomized them to receive either placebo or a buccal formulation of DMT and harmine, 120 mg each, an ayahuasca-inspired combination administered through the cheek tissue rather than as a brewed drink. All participants underwent resting-state pharmaco-fMRI, the kind of brain imaging that captures how regions communicate even when you're not doing anything in particular.

The functional connectivity findings cut against any easy equivalence between sitting and tripping. Meditation alone reduced functional connectivity between brain networks, quieting the chatter across regions. DMT-harmine moved in the opposite direction entirely, increasing both within-network and between-network connectivity. The authors describe these as "distinct neural mechanisms underlying meditation and psychedelic-augmented meditation," and the data backs that language up precisely.

The psychedelic condition did produce something recognizable to anyone familiar with the neuroscience literature on altered states: gradient disruption, which the study describes as "characteristic of acute psychedelic action." Importantly, that disruption was temporary. The researchers noted a "return to typical brain organization shortly after the experience," suggesting the acute rewiring doesn't persist as such into the hours that follow.

The study is notable for addressing a gap in the field. Prior empirical work on the meditation-psychedelic intersection has focused almost entirely on psilocybin, making this DMT-harmine dataset a rare look at a different pharmacological profile in a retreat context. The authors flag both practices as "widely studied for their therapeutic potential in mental health" and call for "further exploration of their synergistic potential in clinical contexts."

For practitioners in the mindfulness community who have watched the psychedelic-assisted therapy conversation grow louder, the research offers a more nuanced frame than popular headlines sometimes allow. The mechanisms aren't the same, but the authors suggest the two may be "complementary" in ways worth studying rigorously, particularly for emotional and psychological well-being. What that complementarity looks like in a clinical protocol is the question this study pointedly leaves open.

The full study is available via PubMed Central (PMCID: PMC12479382; DOI: 10.1162/IMAG.a.907). Co-authors include Daniel Meling, Firuze Polat, Erich Seifritz, Mihai Avram, and Milan Scheidegger.